Sunesis Pharma Loss Narrows in Q4, Widens in 2012

Sunesis Pharmaceuticals  has reported its Q4 and 2012 results.  For the quarter, revenue was just under $2 million. Comprehensive net loss narrowed to $4 million ($0.20 per diluted share) from Q4 2011's red figure of $8.7 million ($0.19). The company did not report any revenue for the latter period.

Analysts had expected revenue of $400,000 and a per-share loss of $0.19 for the most recent quarter.

For the full year, top line was $3.8 million, notably lower than the 2011 figure of $5 million. Comprehensive net loss widened considerably, landing at almost $44 million ($0.91 per diluted share) for the year against 2011's shortfall of $20 million ($0.43).

The article Sunesis Pharma Loss Narrows in Q4, Widens in 2012 originally appeared on

Fool contributor Eric Volkman has no position in Sunesis Pharmaceuticals, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.